about
Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endotheliumActions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK.A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothoraxIdentification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and MetastasisDefective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice.Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia.Viewpoints on vessels and vanishing bones in Gorham-Stout disease.Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.Hyperplasia, de novo lymphangiogenesis, and lymphatic regression in mice with tissue-specific, inducible overexpression of murine VEGF-D.Lymphatic Endothelial Cells Produce M-CSF, Causing Massive Bone Loss in Mice.Mir-126 is a conserved modulator of lymphatic development.VEGF-C promotes the development of lymphatics in bone and bone loss.Somatic activating mutations in cause generalized lymphatic anomalyChy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasiaLymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questionsLymphatics in bone arise from preexisting lymphatics
P50
Q28741586-AB4275C6-F442-4CFD-8BFF-C373866A727FQ34525997-82938D8B-80C2-4DDF-A9C3-FFAF38ECCB9DQ34781478-90FF8334-535E-4639-96F3-1B19B2899C80Q35099297-F1F57FCA-7F90-4149-9DA3-799EF0C147D6Q35947903-50236B97-7649-455A-BCEA-CA8E06296D0AQ36067893-7DF2B288-18BD-41AD-A97E-7E0830D637EDQ36876876-BC1B5940-5236-4EB3-97C3-20A5A20275BEQ38026529-172BF30E-5D9C-4305-9079-269A1076E82CQ38192380-6531FE4D-F5A1-43CC-8EB9-4273EB938590Q39042485-85FF0671-FE80-4C5A-A338-0CA5BB9E9CEEQ39830850-24E21570-0605-4685-9238-E3EA5B56EE05Q42495285-F776EAB9-1AF4-43CE-ADAD-43260C768FD9Q51218133-F247B7CA-1EC5-432E-87A5-C1323CAC7525Q51738957-32B85184-5457-4DC2-AF8B-FB9FFFB884E0Q52605044-BDD0F434-6FFD-487A-B11D-0572F25557A4Q63987380-A56D0E7C-FB74-46C3-9738-B86AB9B387BFQ80512688-BCD03C29-B56D-4596-B9A1-5C2106BAA016Q88886615-2C508474-907F-43F7-A19E-21268FB9D7E0Q90436749-88DF0744-FC3D-4CAE-A36D-F14F1E3E7322
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Dellinger
@ast
Michael Dellinger
@en
Michael Dellinger
@es
Michael Dellinger
@nl
Michael Dellinger
@sl
type
label
Michael Dellinger
@ast
Michael Dellinger
@en
Michael Dellinger
@es
Michael Dellinger
@nl
Michael Dellinger
@sl
prefLabel
Michael Dellinger
@ast
Michael Dellinger
@en
Michael Dellinger
@es
Michael Dellinger
@nl
Michael Dellinger
@sl
P106
P1153
24436436400
P31
P496
0000-0002-3315-4239